selling peptides FAQ

Test reconstituted samples using UV spectrophotometry at 280 nm to detect protein aggregation or degradation before use in live protocols. Lyophilized peptides tolerate short-term temperature excursions better than reconstituted solutions—unreconstituted tirzepatide remains stable at 25°C for up to 48 hours, but once mixed with bacteriostatic water, the same temperature exposure for 12 hours can reduce potency by 15–20%. If shipping took longer than expected or cold-chain documentation is incomplete, discard reconstituted vials and reconstitute fresh aliquots from lyophilized stock stored at −20°C. The cost of replacing a suspect vial is lower than the cost of invalid experimental data.

Discard the solution immediately. Do not attempt to filter or use it. Cloudiness indicates protein aggregation or precipitation, meaning the peptide has denatured and lost its native three-dimensional structure required for receptor binding. This occurs when reconstitution uses incorrect diluent (sterile water instead of bacteriostatic water), when the lyophilized powder was exposed to temperature excursions above 25°C before reconstitution, or when the solution pH falls outside the stability range for that specific peptide. Aggregated peptides cannot be restored to native conformation and will produce null results in research applications.

Combine BPC-157 with TB-500 and dose both compounds simultaneously rather than sequentially. BPC-157 drives angiogenesis and early-phase collagen deposition during days 3–14 post-injury, while TB-500 accelerates cellular migration and matrix remodeling during weeks 2–8. Overlapping the dosing schedules compresses the total healing timeline by 20–30% in animal models because both proliferative and remodeling phases progress concurrently rather than waiting for one to finish before the other begins. The mechanistic synergy. VEGF upregulation from BPC-157 creating vascular scaffolding that TB-500-driven fibroblasts migrate along. Explains why combined protocols consistently outperform sequential dosing in published tendon and ligament repair studies.

Combine BPC-157 with TB-500. The dual mechanism (BPC-157's VEGF upregulation + TB-500's actin-mediated cell migration) produces faster wound closure in scratch assays and animal models than either compound alone. Published studies show 30–40% faster re-epithelialization with combination therapy versus BPC-157 monotherapy. Alternatively, add GHK-Cu to stimulate collagen synthesis concurrently with angiogenesis. This triple-mechanism approach accelerates all three phases of wound healing (inflammation, proliferation, remodeling) simultaneously rather than sequentially.

Request a Certificate of Analysis (CoA) showing HPLC purity and mass spectrometry verification before using any peptide in experiments. Purity below 95% introduces undefined impurities. Truncated sequences, deletion analogs, or synthesis byproducts. That can act as competitive antagonists or trigger off-target receptor binding, fundamentally altering experimental results. If purity falls below specified standards, contact the supplier immediately for replacement rather than attempting to compensate through dose adjustment, which cannot correct for the presence of structurally similar but functionally distinct peptide variants.

Switch to Dihexa or P21. Both are lyophilized peptides that remain stable at −20°C for 24+ months unreconstituted, and Dihexa offers oral administration, eliminating cold-chain logistics entirely post-mixing. If Cerebrolysin's specific neurotrophic profile is essential to your protocol, reconstitute only the volume needed for one week of dosing and refrigerate at 2–8°C in amber vials to minimize light degradation. Most Cerebrolysin protocols use 2–5mL doses administered 5 days per week, so a 10mL reconstitution covers one dosing cycle without requiring freezer access between injections.